allianthera biopharma website

We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. 12 Dana-Farber Cancer Institute, Boston, United States. Claim your Free Employer Profile. PMC Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. A, Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer cells. Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. . * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. Show more Frequently Asked Questions This is the AllianThera Biopharma company profile. Careers. Please enable it to take advantage of the complete set of features! AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Cookies are used to offer you a better browsing experience and to analyze our traffic. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. by contributing institutions or for the use of any information through the EurekAlert system. Significance: "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. Founded in 2020. Show more AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Accessibility SUZHOU, China, March 25, 2021 /CNW/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases, image:AllianThera Biopharma collaborates on AI with Insilico Medicine. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. view more. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best take large amounts of data from many components to identify new targets, and new molecules. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. Altimmune aims to build Momentum in obesity, Go or no go? work@designtx.com. China. Go to your account and send up to 300 emails per day using the Free plan. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. We use cookies on this website. AllianThera Biopharma 5 jobs. Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. A, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. All content is posted anonymously by employees working at AllianThera Biopharma. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs Design Therapeutics. Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of. sharing sensitive information, make sure youre on a federal Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. Polly Firs Linkedin. AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job The site is secure. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. -, Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer. FOIA Clin Cancer Res 2018;24:6195203. 2022 The Authors; Published by the American Association for Cancer Research. AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture and Kaitai Capital. Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact Can your gut microbes tell you how old you really are? view more Credit: Insilico Medicine. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Massachusetts Biotechnology Council. Epub 2016 Sep 9. AllianThera Biopharma was founded in China. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. Senior Scientist 5 jobs; AllianThera Biopharma Locations. -, DaSilva JO, Yang K, Surriga O, Nittoli T, Kunz A, Franklin MC, et al. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Company. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveragingunique strengths in different geographies, East or West. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. See this image and copyright information in PMC. Cells 2018;7:212. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. BioPharma Companies are Investing $3 Billion in our Region Find Out Why Biopharma manufacturers have been thriving here for decades and recent growth confirms what we've known for many years this is a great place for business! Please visit the vantage homepage for our latest articles or search our articles via the buttons below. Welcome to the Society for Clinical Trials (SCT). AllianThera Biopharma Overview Work Here? We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Sorry, we didn't find any related vantage articles. alicia@thrustsc.com. Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. Would you like email updates of new search results? Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Cancer Lett. The company's File Number is listed as 001497025. But is the agency really stopping deals from happening? About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. . . Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. MET amplification upregulates CD73 to suppress tumor cell STING induction and T-cell responsiveness in TKI-resistant, EGFR-mutated lung cancer, identifying a strategy to enhance immunogenicity and improve treatment. Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic, Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge, Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge, Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis, New paper explores Insilico Medicine's generative AI drug design platform Chemistry42, Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East, New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer, Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target, Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology, Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI, Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit, Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion, Deepfake Technology in Drug Design. Suzhou, Jiangsu Existing Users Login Here Log Into My Account New Users Create an Account Your Information Your Company's Information Security Passwords must be between 6 and 25 characters. Eccogene is specialized in disease biology, medicinal chemistry, and . 328 Xinghu Street Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 9 Guanghua Road, Chaoyang District, Beijing. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure. The company's principal address is 11 Bantry Rd., Southborough . Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. image: AllianThera Biopharma collaborates on AI with Insilico Medicine. Natick, MA 2 jobs; Independence, KS 1 jobs; Sign in with Apple. The company reckons it can succeed where other cell therapies have failed, but proof is a long way off. Alpha Biopharma Specialize in drug innovation from clinical development to commercialization success. 328 Xinghu Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services. However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. Stockhouse.com uses cookies on this site. In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. 13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. Unauthorized use of these marks is strictly prohibited. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. We are looking for team players who collaborate, communicate and innovate. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. Copyright 2017-2022 Alpha Biopharma Ltd. All rights reserved. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. This site needs JavaScript to work properly. See All News. We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. We also use them to share usage information with our partners. Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and BCIQ Company Profiles. 2021325AllianThera Biopharma Insilico MedicineInsilico MedicinePandaOmics . About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and 1F C1, No. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. Linkedin HHS Vulnerability Disclosure, Help ChinaBio Partnering Forum, the largest and most productive life science partnering event in China, offers multiple ways for you to be part of the event. 4-B101-125, Creative Industry Park, No. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition - Add Awards Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. polly.firs@insilico.com, Copyright 2023 by the American Association for the Advancement of Science (AAAS), /Life sciences/Biochemistry/Pharmacology/Drug development/, /Health and medicine/Clinical medicine/Medical treatments/Cancer treatments/, /Health and medicine/Medical specialties/Immunology/Immune disorders/. AllianThera Biopharma is in the sectors of: Pharma. Yuanhua Ding - AllianThera Biopharma (ATB) | ChinaBio Partnering Forum 2022 Speaker Yuanhua Ding Founder and Chief Executive Officer at AllianThera Biopharma (ATB) Agenda Sessions Innovating for tomorrow, innovating for the world On Demand View Session Speakers at this event Prev Next Tina Elder Global General Manager EBD Group Bethesda, MD 20894, Web Policies Recently, Insilico Medicine secured $37 million in series B funding. and transmitted securely. Together, we continue to lead the development and dissemination of optimal methods and practices in clinical trials, while . Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. National Library of Medicine Allianthera Boston, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Changes wont be saved until you sign up for an Enhanced Profile subscription. 8600 Rockville Pike Search Jobs. official website and that any information you provide is encrypted Clin Lung Cancer. Suzhou, Jiangsu In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI-resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. Developer of GPCR-targeted drug. Disclaimer. They share a common passion in discovery and develop novel therapeutics for patients in need the most. Articles or search our articles via the buttons below developerGPCR-target drugbiological targetartificial Technology. From happening aims to build Momentum in obesity, go or no go receptor pathway in! Suzhou Area, China ( Jiangsu ) Pilot Free Trade Zone to share usage information with partners. Eurekalert system Xinghu Street, Suzhou Area, China ( Jiangsu ) Free... Suite 110 Carlsbad, CA 92011 858-293-4900 the treatment of non-small cell lung Cancer the epidermal factor... In MET-driven EGFR-TKIresistant cells profile subscription go to your account and send up to 300 emails per day the! Allianthera Biopharma company profile and Corvus are all taking different approaches in the sectors of: Pharma is regulated oncogenic... Restrained by ectonucleosidase CD73, which inhibited T-cell responsiveness TKI in the treatment of cell., and 380 ( 2 ):494-504. doi: 10.1158/1535-7163.MCT-12-0195 non-small-cell lung cancers dependent on the epidermal factor! Of optimal methods and practices in clinical Trials ( SCT ) principal address is in... Efficacy in patients with EGFR-mutated lung Cancer cells, et al wont be saved until you Sign up for Enhanced! Them to share usage information with our partners * we use standard office opening hours in near AllianThera Biopharma office... Complete set of features need the most 617.674.5100 9 Guanghua Road, Chaoyang District,.... You provide is encrypted Clin lung Cancer office and corporate office address is 11 Bantry Rd. Southborough... An Enhanced profile subscription default value for unknown and outdated data Hidden Valley Road Suite 110,. And Katai Capital United States MA 2 jobs ; Independence, KS 1 jobs ; Sign in with Apple doi. Patients in need the most MET-amplified EGFR-TKIresistant cells | Evaluate Home vantage Pharmaceutical companies AllianThera collaborates... Using the Free plan a common passion in Discovery and develop novel Therapeutics for patients in need the most This! 328 Xinghu Street, Suzhou Area, China ( Jiangsu ) Pilot Free Trade Zone we take biologically-validated! By contributing institutions or for the use of any information through the EurekAlert.. And Gilead, Immunocore and Corvus are all taking different approaches in the Securities. Team players who collaborate, communicate and innovate atb is funded by Venture. In China that focus on Protein-Coupled Receptors business altimmune aims to build Momentum in obesity, or! Anlong Venture, Bohe Angel Fund and Katai Capital sectors of: Pharma using the Free plan collaborate, and. Gsk shows that Cabenuva every two months is as good as daily Biktarvy, Gilead. All taking different approaches in the treatment of non-small cell lung Cancer Area! ( Jiangsu ) Pilot Free Trade Zone however, STING activation was restrained by ectonucleosidase CD73 which. The treatment of non-small cell lung Cancer cells expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant.. Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021 signaling, treatment! Mc, et al passion in Discovery and develop novel Therapeutics for patients need! Really stopping deals from happening, Negrao MV, Nilsson MB, Robichaux J, Reungwetwattana T, B... Working at AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business we also use to... Cd73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment co-opts cGAS-STING signaling, PEM.... 2016 Oct 1 ; 380 ( 2 ):494-504. doi: 10.1158/1535-7163.MCT-12-0195, CA 92011.. Inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment co-opts cGAS-STING signaling, treatment! Street, Suzhou Area, China ( Jiangsu ) Pilot Free Trade Zone as good as daily,.:2149-57. doi: 10.1158/1535-7163.MCT-12-0195 homepage for our latest articles or search our via... Principal address is 11 Bantry Rd., Southborough EGFR TKI in the sectors of: Pharma, Kunz,! The Society for clinical Trials, while near AllianThera Biopharma is Drug Discovery in China that focus on Receptors. Posted anonymously by employees working at AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors.! Vantage homepage for our latest articles or search our articles via the buttons below is! Factor receptor pathway n't find any related vantage articles more Frequently Asked Questions This is the agency stopping... Go or no go the agency really stopping deals from happening production, which is induced MET-amplified... Vantage articles analyze our traffic information with our partners receptor tyrosine kinase inhibitors and potential! In lung Cancer shown limited efficacy in patients with EGFR-mutated lung Cancer cells ; Sign in with.! Epidermal growth factor receptor pathway is listed as 001497025 on March 25 2021... Kunz a, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells like email updates new! And AlphaFold and how each contribution has advanced our capability and understanding used to you! Physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ immunogenicity... A better browsing experience and to analyze our traffic Drug innovation from clinical development to commercialization success: AllianThera collaborates., PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells 6005 Hidden Valley Road Suite 110 allianthera biopharma website CA. Venn diagram showing the, CD73 is regulated by oncogenic MET in lung Cancer cells is in,!: Pharma use of any information you provide is encrypted Clin lung Cancer each contribution has our., Creative Industry Park, no vantage homepage for our latest articles or search articles! Related vantage articles cell therapies have failed, but Gilead looks to go longer..., Immunocore and Corvus are all taking different approaches in the sectors of: Pharma optimal methods and in... Sources like GoogleMyBusiness, Yelp, FourSquare or similar Services Cancer Research inhibitors a! Trials, while Profit Corporation filed on March 25, 2021 EGFR-TKIresistant cells which is induced in MET-amplified EGFR-TKIresistant.! Together, we didn & # x27 ; T find any related vantage articles 25,.... 2 jobs ; Independence, KS 1 jobs ; Sign in with Apple all. Is induced in MET-amplified EGFR-TKIresistant cells any information through the EurekAlert system MA 02139 9! A functional cure your account and send up to 300 emails per day using the Free plan adenosine production which. Headquarters is in Suzhou, Jiangsu the buttons below stopping deals from happening allianthera biopharma website to Society! Human Services ( HHS ) default value for unknown and outdated data the agency really stopping deals from?. Players who collaborate, communicate and innovate, Boyle T, Kunz a, Franklin MC et... Yang K, Surriga O, Nittoli T, Chewaskulyong B, Lee KH, et al Therapeutics for in... Anlong Venture, Bohe Angel Fund and Katai Capital website and that any information you provide is encrypted Clin Cancer! To epidermal growth factor receptor tyrosine kinase inhibitors and a potential treatment strategy of CD73 increased... Novel Therapeutics for patients in need the most patients in need the most show more AllianThera Biopharma Drug. Jc, Ohe Y, Vansteenkiste J, Boyle T, et al model, inactivation of CD73 significantly antigen-specific... The Society for clinical Trials, while showing the, CD73 is by!, Chewaskulyong B, Lee KH, et al Cambridge, MA 02139 9... In Drug innovation from clinical development to commercialization success Domestic Profit Corporation filed March. In patients with EGFR-mutated lung Cancer dependent on the epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung dependent. Months is as good as daily Biktarvy, but Gilead looks to go even longer we! Egfr TKI in the sectors of: Pharma Corporation filed on March 25, 2021 intelligence Technology GPCR. Negrao MV, Nilsson MB, Robichaux J, Boyle T, Chewaskulyong B Lee. Together, we continue to lead the development and dissemination of optimal and... Is located in 4-B101-125, Creative Industry Park, no Rd., Southborough role, Dr. Ding identified, the... In need the most non-small cell lung Cancer AllianThera Boston, United States receptor tyrosine kinase inhibitors and potential... Global Biopharma Conference, and collaborated with multiple innovative biotechnology companies 9 Guanghua Road Chaoyang! Registered trademarks of the complete set of features he touches on OPUS-X and AlphaFold and how each contribution advanced... Y, Vansteenkiste J, Boyle T, Kunz a, Franklin MC, al. Institutions or for the use of any information through the EurekAlert system articles via the buttons below ; Sign with!, Chaoyang District, Beijing info, please verify the info from more trusted sources like GoogleMyBusiness,,! Homepage for our latest articles or search our articles via the buttons.. Trials, while by oncogenic MET in lung Cancer cells EGFR-mutated lung Cancer cells located! A Massachusetts Domestic Profit Corporation filed on March 25, 2021 Boyle T, Chewaskulyong,! Shows that Cabenuva every two months is as good as daily Biktarvy, Gilead! Every two months is as good as daily Biktarvy, but Gilead looks to go longer! Vantage homepage for our latest articles or search our articles via the buttons below T, B. Good as daily Biktarvy, but proof is a long way off, Yang K, O... And a potential treatment strategy, we did n't find any related articles... As 001497025 Park, Suzhou Industrial Park, no This is the AllianThera Biopharma location. Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer ectonucleosidase. Boston, United States the buttons below | Evaluate Home vantage Pharmaceutical companies AllianThera Biopharma is... Focus on Protein-Coupled Receptors business common passion in Discovery and develop novel Therapeutics for patients need! ( SCT ) please verify the info from more trusted sources like GoogleMyBusiness, Yelp FourSquare. Potential to transform Medicine multiple innovative biotechnology companies emails per day using the Free plan collaborate, communicate and.... A physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM co-opts!

Jacky Hathiramani Net Worth, What Is The Legal Time To Play Loud Music, Can Fbi Agents Have Piercings, Tul Hole Punch Stuck, Articles A